27 assets in Lymphoproliferative Syndrome

Therapeutic assets addressing Lymphoproliferative Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludarabine Lymphoproliferative Syndrome	Beijing Immunochina Medical Science & Technology Co., Ltd.	P2	BB (66)
Cyclophosphamide Lymphoproliferative Syndrome	Beijing Immunochina Medical Science & Technology Co., Ltd.	P2	BB (64)
Tabelecleucel Lymphoproliferative Syndrome	Pierre Fabre Medicament	P3	BB (64)
Busulfanum Lymphoproliferative Syndrome	M.D. Anderson Cancer Center	P2	B (63)
Rituximab Lymphoproliferative Syndrome	Emory University	P2	B (63)
Tacrolimus Lymphoproliferative Syndrome	M.D. Anderson Cancer Center	P2	B (62)
Ibrutinib Lymphoproliferative Syndrome	Oncternal Therapeutics, Inc	P3	B (60)
Nivolumab Lymphoproliferative Syndrome	National Cancer Institute (NCI)	P2	B (60)
Ondansetron Lymphoproliferative Syndrome	UNC Lineberger Comprehensive Cancer Center	P2	B (60)
Zilovertamab Lymphoproliferative Syndrome	Oncternal Therapeutics, Inc	P3	B (60)
Alectinib Lymphoproliferative Syndrome	Cancer Research UK	P2/3	B (57)
Atezolizumab Lymphoproliferative Syndrome	Cancer Research UK	P2/3	B (57)
Entrectinib Lymphoproliferative Syndrome	Cancer Research UK	P2/3	B (57)
Nivestim Lymphoproliferative Syndrome	National Cancer Institute (NCI)	P2	B (57)
Dabrafenib Lymphoproliferative Syndrome	Cancer Research UK	P2/3	B (56)
Trametinib Lymphoproliferative Syndrome	Cancer Research UK	P2/3	B (56)
Acalabrutinib Lymphoproliferative Syndrome	Emory University	P2	CCC (53)
Atl-Ric Lymphoproliferative Syndrome	National Cancer Institute (NCI)	P2	CCC (53)
Ioc Lymphoproliferative Syndrome	National Cancer Institute (NCI)	P2	CCC (53)
Obinutuzumab Lymphoproliferative Syndrome	Emory University	P2	CCC (53)
Thiotepa Lymphoproliferative Syndrome	M.D. Anderson Cancer Center	P2	CCC (53)
IM19 CAR-T cells Lymphoproliferative Syndrome	Beijing Immunochina Medical Science & Technology Co., Ltd.	P1/2	CC (47)
Atlcar.Cd30.Ccr4 Cells Lymphoproliferative Syndrome	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Bendamustine Lymphoproliferative Syndrome	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Ebv-Specific T Cells: B Lymphoproliferative Syndrome	Baylor College of Medicine	P1	CC (43)
Kln-1010 Lymphoproliferative Syndrome	Kelonia Therapeutics, Inc.	P1	CC (43)
Oricar-017 Lymphoproliferative Syndrome	OriCell Therapeutics Co., Ltd.	P1	CC (43)